Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Shield Therapeutics Temettü
Temettü kriter kontrolleri 0/6
Shield Therapeutics does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
n/a
Ödeme oranı
Sektör ortalama getirisi | 2.3% |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | n/a |
Hisse başına kazanç | -UK£0.046 |
Temettü verim tahmini | 0% |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if STX's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if STX's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
Shield Therapeutics Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (STX) | n/a |
Pazarın Alt %25'i (GB) | 2.1% |
Pazarın En İyi %25'i (GB) | 5.5% |
Sektör Ortalaması (Pharmaceuticals) | 2.3% |
Analist tahmini (STX) (3 yıla kadar) | 0% |
Önemli Temettü: Unable to evaluate STX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate STX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate STX's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as STX has not reported any payouts.